Clinical trial
Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma…
NCT00193609 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00193609 |
|---|---|
| Title | Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site |
| Official title | A Phase II Trial of Oxaliplatin and Capecitabine in the Treatment of Patients With Relapsed/Refractory Carcinoma of Unknown Primary Site |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | Roche Pharma AG Industry Sanofi-Synthelabo |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neoplasms, Unknown Primary |
| Intervention type | Drug |
| Interventions | Oxaliplatin, Capecitabine |
| Enrollment | 48 |
| Start date | Sep 1, 2004 |
| Primary completion | Apr 1, 2008 |
| Completion | Jan 1, 2009 |
| First posted | Sep 19, 2005 |
| Last update posted | Nov 11, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: